| Literature DB >> 28480394 |
Haoxuan Luo1, Yan Chen2, Baoguo Sun1, Ting Xiang1, Shijun Zhang1.
Abstract
BACKGROUND: Spleen-deficiency syndrome (SDS) in Traditional Chinese Medicine (TCM) played pivotal roles on the development of hepatocellular carcinoma (HCC). This study was performed to establish and evaluate HCC model in mice with SDS in TCM.Entities:
Keywords: Evaluation; Hepatocellular carcinoma; Mice model; Spleen-deficiency; Traditional Chinese Medicine
Mesh:
Year: 2016 PMID: 28480394 PMCID: PMC5411868 DOI: 10.21010/ajtcam.v14i1.18
Source DB: PubMed Journal: Afr J Tradit Complement Altern Med ISSN: 2505-0044
The evaluation standard of Spleen Deficiency Syndrome Score.
| 1 | 2 | 3 | 4 | |
|---|---|---|---|---|
| Odor-free | Mild odor | Medium odor | Severe odor | |
| Stable | Irritable | Fatigue | Somnolence | |
| Normal | Cowered | Chill | Arched back & trembling | |
| Normal | Panting | Tachypnea | Faint | |
| Gloss | Matted | Fluffy & erect | Brown & erect | |
| Formed | Loose | Wet & loose | Mucous | |
| Normal | Reduced to 50% | Reduced to 25% | Not at all |
Figure 1General state of animal models. (A) A visible 10 mm-diameter tumor raised up from the skin of the nude BALB/c mouse while being injected the hepal-6 mouse HCC cell lines subcutaneously to the back; (B) The mouse which received the SDS modeling showed typical spleen-deficiency syndrome such as fatigue, arched back with trembling, faint especially the brown and erected fur; (C, D) The dissection for tissue preparation showed the tumors had been formatted visibly in the OHCC and DHCC models respectively. HCC, Hepatocellular carcinoma; SDS, Spleen-deficiency syndrome; OHCC, Orthotopic hepatocellular carcinoma; DHCC, Drug-induced hepatocellular carcinoma.
Figure 2The evaluation of SDS models by SDS scores. *P<0.05 vs. Control group; #P<0.05 vs. OHCC group; & P<0.05 vs. DHCC group. SDS, Spleen-deficiency syndrome; OHCC, Orthotopic hepatocellular carcinoma; DHCC, Drug-induced hepatocellular carcinoma.
Figure 3Tumor formation rate and survival time of HCC model mice. (A) Tumor formation rate of the mice in HCC models. (B) Survival time of the mice in HCC models. *P<0.05 vs. OHCC group; #P<0.05 vs. DHCC group. HCC, Hepatocellular carcinoma; SDS, Spleen-deficiency syndrome; OHCC, Orthotopic hepatocellular carcinoma; DHCC, Drug-induced hepatocellular carcinoma.
Figure 4